- Home
- BIIB vs GFS Comparison
BIIB vs GFS Comparison
Compare BIIB & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- GFS
- Stock Information
- Founded
- BIIB 1978
- GFS 2009
- Country
- BIIB United States
- GFS United States
- Employees
- BIIB N/A
- GFS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- GFS Semiconductors
- Sector
- BIIB Health Care
- GFS Technology
- Exchange
- BIIB Nasdaq
- GFS Nasdaq
- Market Cap
- BIIB 25.1B
- GFS 22.5B
- IPO Year
- BIIB 1991
- GFS 2021
- Fundamental
- Price
- BIIB $157.78
- GFS $44.88
- Analyst Decision
- BIIB Buy
- GFS Buy
- Analyst Count
- BIIB 25
- GFS 15
- Target Price
- BIIB $258.57
- GFS $51.07
- AVG Volume (30 Days)
- BIIB 1.6M
- GFS 1.8M
- Earning Date
- BIIB 10-30-2024
- GFS 11-05-2024
- Dividend Yield
- BIIB N/A
- GFS N/A
- EPS Growth
- BIIB 10.05
- GFS N/A
- EPS
- BIIB 11.06
- GFS 1.32
- Revenue
- BIIB $9,607,500,000.00
- GFS $6,774,000,000.00
- Revenue This Year
- BIIB N/A
- GFS N/A
- Revenue Next Year
- BIIB N/A
- GFS $9.81
- P/E Ratio
- BIIB $14.26
- GFS $34.01
- Revenue Growth
- BIIB N/A
- GFS N/A
- 52 Week Low
- BIIB $153.62
- GFS $35.85
- 52 Week High
- BIIB $268.30
- GFS $62.61
- Technical
- Relative Strength Index (RSI)
- BIIB 33.43
- GFS 58.44
- Support Level
- BIIB $158.44
- GFS $44.00
- Resistance Level
- BIIB $162.62
- GFS $45.74
- Average True Range (ATR)
- BIIB 3.19
- GFS 1.38
- MACD
- BIIB 0.90
- GFS 0.11
- Stochastic Oscillator
- BIIB 35.65
- GFS 81.75
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About GFS GlobalFoundries Inc.
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 12,000 people.